Sugi Predict

Sugi Predict / Compounds / SCHEMBL940976

SCHEMBL940976

SCHEMBL940976

CCC[CH]C(C)CCCCCC

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 1/20 0.42
▸ ADH1B P00325 1/20 0.42
▸ ADH1C P00326 1/20 0.42
▸ ADH1A P07327 1/20 0.42
▸ ADH4 P08319 1/20 0.42
▸ ADH7 P40394 1/20 0.42
▸ SPHK1 Q9NYA1 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ DNM1 Q05193 5/20 0.39
▸ TSHR P16473 3/20 0.38
▸ THRB P10828 1/20 0.38
▸ ACE2 Q9BYF1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28270182 1.00 OPRM1 (0.42) OPRM1ADH1BADH1CADH1AADH4
SCHEMBL28219926 1.00 OPRM1 (0.42) OPRM1ADH1BADH1CADH1AADH4
SCHEMBL28279026 1.00 OPRM1 (0.42) OPRM1ADH1BADH1CADH1AADH4
SCHEMBL28270193 1.00 OPRM1 (0.42) OPRM1ADH1BADH1CADH1AADH4
SCHEMBL28616974 1.00 OPRM1 (0.42) OPRM1ADH1BADH1CADH1AADH4
SCHEMBL28219919 1.00 OPRM1 (0.42) OPRM1ADH1BADH1CADH1AADH4
SCHEMBL9866884 0.98 OPRM1 (0.44) OPRM1ADH1BADH1CADH1AADH4
SCHEMBL5091088 0.91 OPRM1 (0.42) OPRM1ADH1BADH1CADH1AADH4
SCHEMBL1900761 0.91 TSHR (0.42) OPRM1ADH1BADH1CADH1AADH4
SCHEMBL13279660 0.91 TSHR (0.42) OPRM1ADH1BADH1CADH1AADH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226313-A1 CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF SEAGEN INC. 2024-07-11 — — US disclosed
US-12029736-B2 Camptothecin derivatives and conjugates thereof MEDIBOSTON LIMITED (HK) 2024-07-09 — — US disclosed
US-20240199534-A1 CYCLOPROPANE ANALOGUES OF N-(TRANS-4-HYDROXYCYCLOHEXYL)-6-PHENYLHEXANAMIDE AND RELATED COMPOUNDS DORN, GERALD W., II, DR. 2024-06-20 — — US disclosed
CN-117957023-A Lectin-drug conjugates 联合化学实验室有限公司 2024-04-30 — — CN disclosed
US-11964025-B2 Peptide-containing linkers for antibody-drug conjugates MERSANA THERAPEUTICS, INC. (US) 2024-04-23 — — US disclosed
EP-2850094-B1 SELF-STABILIZING LINKER CONJUGATES SEAGEN INC (US) 2024-04-17 — — EP disclosed
US-20240108744-A1 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF FORTVITA BIOLOGICS LIMITED (CN) 2024-04-04 — — US disclosed
WO-2024023735-A1 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF MEDIBOSTON LIMITED (CN) 2024-02-01 — — WO disclosed
EP-4308540-A1 CYCLOPROPANE ANALOGUES OF N-(TRANS-4-HYDROXYCYCLOHEXYL)-6-PHENYLHEXANAMIDE AND RELATED COMPOUNDS Mitochondria Emotion, Inc. (US) 2024-01-24 — — EP disclosed
EP-4297797-A2 ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF MediBoston Limited (HK) 2024-01-03 — — EP disclosed
EP-2850094-A2 SELF-STABILIZING LINKER CONJUGATES Seattle Genetics, Inc. (US) 2015-03-25 — — EP disclosed
EP-2842575-A1 Auristatin drug linker conjugates Seattle Genetics, Inc. (US) 2015-03-04 — — EP disclosed
EP-2265283-B1 AURISTATIN DRUG LINKER CONJUGATES SEATTLE GENETICS INC (US) 2014-09-03 — — EP disclosed
US-20140050746-A1 AURISTATIN DRUG LINKER CONJUGATES SEATTLE GENETICS, INC. (US) 2014-02-20 — — US disclosed
US-8609105-B2 Auristatin drug linker conjugates SEATTLE GENETICS, INC. (US) 2013-12-17 — — US disclosed
US-20130309256-A1 SELF-STABILIZING LINKER CONJUGATES SEAGEN INC. 2013-11-21 — — US disclosed
WO-2013173337-A2 SELF-STABILIZING LINKER CONJUGATES SEATTLE GENETICS, INC. (US) 2013-11-21 — — WO disclosed
US-20110020343-A1 AURISTATIN DRUG LINKER CONJUGATES SEATTLE GENETICS, INC. (US) 2011-01-27 — — US disclosed
EP-2265283-A1 AURISTATIN DRUG LINKER CONJUGATES Seattle Genetics, Inc. (US) 2010-12-29 — — EP disclosed
WO-2009117531-A1 AURISTATIN DRUG LINKER CONJUGATES SEATTLE GENETICS, INC. (US) 2009-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226313-A1 CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF EPCAM, TOP2A, SPAG5 OPRM1 3023/4885ADH1B 3695/4885ADH1C 1950/4885
US-20130309256-A1 SELF-STABILIZING LINKER CONJUGATES BCR, CD44, FOLR1 OPRM1 1517/4885ADH1B 4382/4885ADH1C 3036/4885
US-20110020343-A1 AURISTATIN DRUG LINKER CONJUGATES AURKA, AURKC, AURKB OPRM1 3430/4885ADH1B 4274/4885ADH1C 3780/4885
US-12029736-B2 Camptothecin derivatives and conjugates thereof TOP2A, TOP1, XPA OPRM1 4853/4885ADH1B 2652/4885ADH1C 3927/4885
US-20240199534-A1 CYCLOPROPANE ANALOGUES OF N-(TRANS-4-HYDROXYCYCLOHEXYL)-6-PHENYLHEXANAMIDE AND RELATED COMPOUNDS HAGH, HADHA, NLN OPRM1 2109/4885ADH1B 440/4885ADH1C 847/4885
US-20140050746-A1 AURISTATIN DRUG LINKER CONJUGATES AURKA, AURKC, AURKB OPRM1 3430/4885ADH1B 4274/4885ADH1C 3780/4885
US-20240108744-A1 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF AURKA, AURKC, AURKB OPRM1 4829/4885ADH1B 2661/4885ADH1C 4181/4885
US-11964025-B2 Peptide-containing linkers for antibody-drug conjugates CD2BP2, DNPEP, LNPEP OPRM1 3733/4885ADH1B 4633/4885ADH1C 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.